Fennec Pharmaceuticals Inc. (FENC): Price and Financial Metrics

Fennec Pharmaceuticals Inc. (FENC): $8.55

0.23 (+2.76%)

POWR Rating

Component Grades













FENC Stock Price Chart Interactive Chart >

Price chart for FENC

FENC Price/Volume Stats

Current price $8.55 52-week high $10.85
Prev. close $8.32 52-week low $5.00
Day low $7.98 Volume 218,300
Day high $8.71 Avg. volume 95,562
50-day MA $9.11 Dividend yield N/A
200-day MA $8.15 Market Cap 225.77M

Fennec Pharmaceuticals Inc. (FENC) Company Bio

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was founded in 1996 and is based in Research Triangle Park, North Carolina.

FENC Latest News Stream

Event/Time News Detail
Loading, please wait...

FENC Latest Social Stream

Loading social stream, please wait...

View Full FENC Social Stream

Latest FENC News From Around the Web

Below are the latest news stories about FENNEC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate FENC as an investment opportunity.

7 Biotech Stocks Sitting in the Sweet Spot

Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | March 24, 2023

Why Earnings Season Could Be Great for Adherex Technologies (FENC)

Adherex Technologies (FENC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 23, 2023

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ Orphan Drug Exclusivity Provides Seven Years of Market Exclusivity for PEDMARK® from its FDA Approval on September 20, 2022 Until September 20, 2029 ~ ~ Additionally, the Company Has Three FDA Orange Book Listings Providing U.S. Patent Protection for PEDMARK® Until 2039 ~ RESEARCH TRIANGLE PARK, N.C., Jan

Yahoo | January 31, 2023

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~ The 5-year Survival Rate for Childhood Cancers Due to Major Treatment Advances is Now 85 Percent or Higher,1 Underscoring Need to Mitigate the Profound Impact Hearing Loss Can Have on a Child’s Learning and Development ~ RESEARCH TRIANGLE PARK, N.C., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals

Yahoo | January 25, 2023

RTP drugmaker Fennec sues Cipla over generics effort

Cipla Ltd. wants to make generic versions of Research Triangle Park drugmaker Fennec's lone product.

Yahoo | January 23, 2023

Read More 'FENC' Stories Here

FENC Price Returns

1-mo -6.46%
3-mo -10.94%
6-mo 5.56%
1-year 52.68%
3-year 187.88%
5-year 41.38%
YTD -10.94%
2022 118.18%
2021 18.12%
2020 14.79%
2019 1.72%
2018 -36.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7483 seconds.